Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.iCo Therapeutics has acquired the exclusive worldwide rights to iCo-009, an oral reformulation of Amphotericin B for the treatment of systemic fungal infections and Leishmaniasis.
Subscribe to our email newsletter
AmpB is a generic drug that has been in use for approximately 50 years and is considered one of the most effective agents in the treatment of systemic fungal infections. Current use of Amp B is limited as it is currently administered intravenously and has significant infusion related side effects and kidney toxicity.
Andrew Rae, iCo’s president & CEO, said: “iCo views the enormous market and compassionate use potential of a novel, oral Amphotericin drug as a win-win scenario for shareholders and our global community alike.”